CRO Solutions has launched VxP Pharma, a wholly-owned subsidiary. VxP Pharma offers the combined services of the independently owned and operated "niche" CROs of its parent company. VxP Pharma will offer pharmaceutical development services and technical support from discovery through phase IIb.

The majority of VxP Pharma's labs are in the U.S., although it also has facilities in Europe and Asia. All sites have been fully audited by CRO Solutions and VxP Pharma, as well as by global pharmaceutical and biotechnology clients. Most sites also have been audited by the FDA and other  regulatory agencies.

"Pharmaceutical and biotech research scientists throughout the industry tell us that they prefer to work with smaller, focused CROs, rather than with the huge multinational 'one-size-fits-all' CROs,” said Raymond E Peck, VxP Pharma chief executive officer. “For these people, VxP Pharma fits because we offer a single point of contact. Because VxP consists of smaller, independently owned and operated facilities that focus only on one area of drug development, our clients get all the advantages of working directly with a specialist ‘niche’ CRO."